Polyphor: Surges as key drug receives QIDP designation in four new indications

Spexis AG

12/04/2019 10:13

** Shares in Swiss biotech co Polyphor  POLN.S  surge 12
pct, set for best day since co's listing in May 2018 
    ** Co says its Murepavadin receives US Food and Drug
Administration (FDA) qualified infectious disease product (QIDP)
designation in four new indications  urn:newsml:reuters.com:*:nASP001084
    ** It adds co will get incentives for development of the
drug, such as eligibility for priority review and Fast Track
designation for these indications
    ** Says additionally five-year extension of market
exclusivity will be granted upon approval of first QIDP
indication
    ** Murepavadin is pathogen specific antibiotic being
developed to treat a deadly strain of pneumonia

 ((Linda.pasquini@tr.com))